Lipoxen signs Russian deal

18 Nov 2009 | News

Collaboration

The biologics drug delivery company Lipoxen plc has signed a collaboration agreement with Pharmasynthez ZAO, a Russian private research-based pharmaceutical company, to apply Lipoxen’s ImuXen and PolyXen proprietary technologies to six drug and vaccine products.

Lipoxen will provide scientific supervision to Pharmsynthez for candidate optimisation and clinical proof of concept trials will be funded by Pharmsynthez.

Lipoxen will have access to all relevant clinical data arising from the subsequent clinical trials for use in developing their products in other markets.

Pharmsynthez will apply Lipoxen’s ImuXen technology to create three enhanced vaccine candidates, for secondary progressive multiple sclerosis, HIV and non-Hodgkin’s lymphoma. Similarly, Lipoxen’s PolyXen technology will be applied to active compounds targeting cystic fibrosis, acute myeloid leukaemia, non-Hodgkin’s lymphoma and Type II diabetes.

Never miss an update from Science|Business:   Newsletter sign-up